3.74
price down icon4.10%   -0.16
after-market 시간 외 거래: 3.74
loading

Verastem Inc 주식(VSTM)의 최신 뉴스

pulisher
Nov 04, 2024

Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com

Nov 04, 2024
pulisher
Nov 02, 2024

Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times

Nov 02, 2024
pulisher
Nov 01, 2024

Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace

Oct 31, 2024
pulisher
Oct 30, 2024

SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 30, 2024
pulisher
Oct 24, 2024

Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India

Oct 24, 2024
pulisher
Oct 21, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 21, 2024
pulisher
Oct 18, 2024

Verastem preps an NDA as the stock struggles - BioWorld Online

Oct 18, 2024
pulisher
Oct 18, 2024

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders

Oct 18, 2024
pulisher
Oct 17, 2024

Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK

Oct 17, 2024
pulisher
Oct 17, 2024

Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan

Oct 17, 2024
pulisher
Oct 15, 2024

This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News

Oct 15, 2024
pulisher
Oct 14, 2024

Verastem Inc (VSTM) stock: A year of ups and downs - US Post News

Oct 14, 2024
pulisher
Oct 10, 2024

Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 09, 2024

Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan

Oct 09, 2024
pulisher
Oct 07, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 07, 2024
pulisher
Oct 05, 2024

Verastem whipsaws after updates for cancer drug combo - MSN

Oct 05, 2024
pulisher
Oct 03, 2024

Taking the lead: Verastem Inc (VSTM) - SETE News

Oct 03, 2024
pulisher
Oct 02, 2024

Guggenheim’s latest rating for VSTM stock - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Verastem Inc’s results are impressive - US Post News

Oct 02, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq

Oct 01, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal phase By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal phase - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Verastem (NASDAQ:VSTM) Receives New Coverage from Analysts at Guggenheim - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Guggenheim Initiates Coverage of Verastem (LSE:0LOV) with Buy Recommendation - Nasdaq

Sep 30, 2024
pulisher
Sep 26, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of “Buy” by Analysts - Defense World

Sep 26, 2024
pulisher
Sep 25, 2024

Verastem CFO sells shares worth $257 to cover tax obligations - Investing.com India

Sep 25, 2024
pulisher
Sep 24, 2024

Verastem CFO sells shares worth $257 to cover tax obligations By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Financial Analysis: Verastem Inc (VSTM)’s Ratios Unveil Key Insights - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Does Verona Pharma Plc ADR (NASDAQ: VRNA) Still Look Hot This Week? - Stocks Register

Sep 24, 2024
pulisher
Sep 24, 2024

Verona Pharma Plc ADR (VRNA) deserves closer scrutiny - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Evan/ Fa Jones Sells 5,173 Shares of Veracyte, Inc. (NASDAQ:VCYT) Stock - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Stock Surge: Viridian Therapeutics Inc (VRDN) Closes at 22.30, Marking a -0.89 Increase/Decrease - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Are Smart Investors Making the Right Decision? Verastem Inc (VSTM) - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Makes New $527,000 Investment in Savara Inc (NASDAQ:SVRA) - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

Acadian Asset Management LLC Takes $82,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Verastem CEO sells shares worth $513 to cover tax obligations - Investing.com India

Sep 21, 2024
pulisher
Sep 20, 2024

Verastem CEO sells shares worth $513 to cover tax obligations By Investing.com - Investing.com South Africa

Sep 20, 2024
pulisher
Sep 20, 2024

Verastem director sells shares worth $365 to meet tax obligations By Investing.com - Investing.com Australia

Sep 20, 2024
pulisher
Sep 20, 2024

Verastem director Brian Stuglik sells shares worth $937 By Investing.com - Investing.com South Africa

Sep 20, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):